Information Provided By:
Fly News Breaks for January 19, 2016
CMRX
Jan 19, 2016 | 06:24 EDT
Piper Jaffray analyst Joshua Schimmer raised his price target for Chimerix to $18 citing increased conviction that brinci will prove to be an approvable drug for adenovirus and smallpox, and potentially for allogeneic transplant and solid organ transplant. The analyst sees a "number of clear paths to value creation" and keeps an Overweight rating on the shares. The stock is trading with a sub-zero enterprise value, Schimmer tells investors in a research note.
News For CMRX From the Last 2 Days
There are no results for your query CMRX